Danilon Equidos Gold 1.5 g Granules for Horses and Ponies

দেশ: যুক্তরাজ্য

ভাষা: ইংরেজি

সূত্র: VMD (Veterinary Medicines Directorate)

সক্রিয় উপাদান:

Suxibuzone

থেকে পাওয়া:

Ecuphar Veterinaria S.L.U.

এটিসি কোড:

QM01AA90

INN (আন্তর্জাতিক নাম):

Suxibuzone

ফার্মাসিউটিকাল ফর্ম:

Granules

প্রেসক্রিপশন টাইপ:

POM-V - Prescription Only Medicine – Veterinarian

থেরাপিউটিক গ্রুপ:

Horses

থেরাপিউটিক এলাকা:

Anti Inflammatory NSAID

অনুমোদন অবস্থা:

Authorized

অনুমোদন তারিখ:

2020-09-10

পণ্য বৈশিষ্ট্য

Revised: February 2022
AN: 02680/2021
Page 1 of 6
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Danilon Equidos Gold 1.5 g Granules for horses and ponies
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 3 g sachet contains: ACTIVE SUBSTANCE:
Suxibuzone (microencapsulated) 1.5 g
EXCIPIENT(S):
Tartrazine (E102)
0.37 mg
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Granules.
Yellow granules.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Horses and ponies.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Treatment of pain and inflammation associated with musculo-skeletal
conditions in
the horse _eg_ osteoarthritic conditions, bursitis, laminitis and soft
tissue inflammation.
4.3
CONTRAINDICATIONS
Do not use in animals with renal, hepatic or cardiac disorders.
Do not use in animals where there is the possibility of
gastro-intestinal ulceration or
bleeding.
Do not use in animals where there is evidence of a blood dyscrasia.
Do not use in known cases of hypersensitivity to the active substance
or any of the
excipient
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
NSAIDs can cause inhibition of phagocytosis and hence, in the
treatment of
inflammatory conditions associated with bacterial infections
appropriate antimicrobial
therapy should be instigated.
Revised: February 2022
AN: 02680/2021
Page 2 of 6
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
Do not exceed the stated dose or duration of treatment. Dosage should
be kept to a
minimum for alleviation of symptoms.
During treatment of very young animals (less than 12 weeks) where
development of
their hepatic or renal function may be incomplete, or in aged animals
which may have
these functions impaired, as well as in ponies, additional risk may be
involved. In
these cases, the posology should be adjusted and patients monitored
closely.
During treatment, do not restrict the consumption of water. Avoid use
in any
dehydrated, hypovolaemic or hypotensive animals as there may be an
increased